Walmsley, Sharon
Smith, Don E.
Górgolas, Miguel
Cahn, Pedro E.
Lutz, Thomas
Lacombe, Karine
Kumar, Princy N.
Wynne, Brian
Grove, Richard
Bontempo, Gilda
Moodley, Riya
Okoli, Chinyere
Kisare, Michelle
Jones, Bryn
Clark, Andrew
Ait-Khaled, Mounir
Clinical trials referenced in this document:
Documents that mention this clinical trial
Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies
https://doi.org/10.1186/s12981-024-00604-9
Documents that mention this clinical trial
Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies
https://doi.org/10.1186/s12981-024-00604-9
Funding for this research was provided by:
ViiV Healthcare
Article History
Received: 13 December 2023
Accepted: 13 March 2024
First Online: 21 March 2024
Declarations
:
: Both studies were conducted in accordance with the International Conference on Harmonization Good Clinical Practice and followed the principles of the Declaration of Helsinki; all participants provided written informed consent before study initiation.
: Not applicable.
: SW has received investigator-initiated grants from Gilead Sciences, Merck, and ViiV Healthcare and has participated in advisory boards for Merck and ViiV Healthcare. DES has served as a consultant for Gilead Sciences and ViiV Healthcare. MG has received grants from Janssen and ViiV Healthcare and consulting fees and honoraria from Janssen, Gilead Sciences, and ViiV Healthcare. PEC has received consulting fees from Gilead Sciences, MSD, and ViiV Healthcare and honoraria from Gilead Sciences and ViiV Healthcare, and has participated in data safety monitoring or advisory boards for Moderna. TL has received funding from GSK, paid to his institution, and grants from Charité Berlin, DAGNÄ e.V., Gilead Sciences, Heidelberg ImmunoTherapeutics GmbH, Leberstiftungs-GmbH, Moderna, and MSD, paid to his institution. KL has received honoraria and travel support from Gilead Sciences, MSD, and ViiV Healthcare. PNK has received grants from Gilead Sciences, GSK, Merck, TheraTechnologies, and ViiV Healthcare, paid to her institution; has received consulting fees from Gilead Sciences, GSK, Merck, and ViiV Healthcare; has participated in data safety monitoring or advisory boards for Gilead Sciences, GSK, Merck, and ViiV Healthcare; and holds stock or stock options in Gilead Sciences, GSK, Johnson & Johnson, Merck, Moderna, and Pfizer. BW, RG, GB, RM, CO, MK, BJ, AC, and MA-K are employees of ViiV Healthcare or GSK and may own stock in GSK.